Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2020 - 12 - 02 save search
Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical
Published: 2020-06-15 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 103.97%
H: 1.56%
C: -26.46%
biotech positive results phase 3
Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2020-10-06 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 2.25%
H: 2.2%
C: 1.1%
biotech phase 3 treatment
Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
Published: 2020-12-02 (Crawled : 16:00) - biospace.com/
INSM | $24.065 -2.96% 790K
|
Health Technology
|
| O: -0.05%
H: 3.71%
C: 1.61%
phase 3
Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With Acute Respiratory Distress Syndrome
Published: 2020-09-04 (Crawled : 14:27) - globenewswire.com
MESO | $5.16 0.98% 100K
|
Health Technology
|
| O: -0.22%
H: 0.9%
C: -6.01%
covid respiratory phase 3 trial syndros
Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
Published: 2020-10-13 (Crawled : 14:27) - globenewswire.com
MESO | $5.16 0.98% 100K
|
Health Technology
|
| O: -0.08%
H: 1.42%
C: 0.33%
covid respiratory phase 3 trial syndros enroll
Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS
Published: 2020-11-11 (Crawled : 14:26) - globenewswire.com
MESO | $5.16 0.98% 100K
|
Health Technology
|
| O: 3.36%
H: 0.83%
C: -1.58%
covid results phase 3 trial
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
Published: 2020-12-02 (Crawled : 14:00) - globenewswire.com
ALLO | $3.415 -1.3% 560K
|
Health Technology
|
| O: -0.97%
H: 2.72%
C: -0.44%
phase 3 phase 1 phase 2
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
FGEN | $1.075 -8.12% 650K
|
Health Technology
|
| O: -0.32%
H: 3.62%
C: 2.15%
phase 3
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.